

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA535)
NICE GUIDANCE ISSUED JULY 2018**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1817 – October 2017

Lenvatinib (Lenvima[®]) 4 mg and 10 mg hard capsules

Submission by Eisai Ltd

Recommendation of AWMSG

Lenvatinib (Lenvima[®]) is recommended as an option for use within NHS Wales for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that lenvatinib (Lenvima[®]) satisfied the AWMSG criteria for orphan/ultra-orphan status/a medicine developed specifically for rare diseases.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 976), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1817:
Lenvatinib (Lenvima[®]) 4 mg and 10 mg hard capsules October 2017



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.